Ixekizumab in the treatment of psoriatic arthritis

Psoriatic arthritis (PsA) is a heterogeneous chronic rheumatic disorder with numerous phenotypic facets. A better in deep understanding of the pathophysiologic mechanisms leading to psoriasis and PsA has contributed to the introduction of novel therapeutic agents. IL-17 is at the heart and a critical factor in the onset of PsA. Ixekizumab, a high-affinity monoclonal antibody against IL-17 A, has been approved by the US FDA in March 2016 for baseline psoriasis and Dec 2017 for PsA; by the EMA in April 2016 and January 2018, respectively. This article reviews the published data relating to ixekizumab efficacy and safety in the PsA treatment.

Automated summary

Psoriatic arthritis (PsA) is a chronic rheumatic disorder with various phenotypic features. IL-17 plays a critical role in the onset of PsA, and the monoclonal antibody Ixekizumab, targeting IL-17A, has shown promising efficacy and safety in PsA treatment.